Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN N versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN N versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
CORDRAN N vs NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
None Documented
None Documented
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Category C
Category D/X
Topical Corticosteroid + Antibiotic
Antibiotic